Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic seminoma with International Germ Cell Consensus Classification (IGCCCG) good prognosis.~2. Glomerular filtration rate (GFR) by Ethylenediaminetetraacetic acid (EDTA) clearance over 25 ml/min.~3. Eastern Cooperative Oncology Group (ECOG) Performance status 0-3.~4. Normal Alpha-fetoprotein (All levels of Human chorionic gonadotropin and Lactate dehydrogenase are acceptable).~5. Males aged ≥18 and ≤75 years.~6. Able to give written informed consent prior to study entry.~7. Patients must be sterile or agree to use adequate contraception during the period of therapy.~Exclusion Criteria:~1. Metastatic seminoma with any non-pulmonary visceral metastases.~2. Raised Alpha-fetoprotein.~3. Any previous chemotherapy or radiotherapy.~4. Currently enrolled in any other investigational drug study.~5. Other malignancy except basal cell.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Carboplatin AUC-10 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).